- Home
- STNG vs MLYS Comparison
STNG vs MLYS Comparison
Compare STNG & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STNG | MLYS |
|---|---|---|
| Founded | 2009 | 2019 |
| Country | Monaco | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.0B | 2.4B |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | STNG | MLYS |
|---|---|---|
| Price | $69.41 | $23.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $79.00 | $48.67 |
| AVG Volume (30 Days) | ★ 1.2M | 1.0M |
| Earning Date | 04-30-2026 | 03-12-2026 |
| Dividend Yield | ★ 2.63% | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.06 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $31.62 | $10.44 |
| 52 Week High | $81.85 | $47.65 |
Technical Indicators
Market Signals| Indicator | STNG | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 46.75 | 28.55 |
| Support Level | $57.95 | $13.42 |
| Resistance Level | $81.85 | $31.09 |
| Average True Range (ATR) | 2.94 | 1.78 |
| MACD | -1.47 | -0.29 |
| Stochastic Oscillator | 20.10 | 4.67 |
Price Performance
Historical ComparisonAbout STNG Scorpio Tankers Inc.
Scorpio Tankers Inc is a provider of marine transportation of petroleum products. It owned, lease financed, or chartered in vessels spanning three different vessel segments Handymax, MR, and LR2. The company's fleet of tankers is the eco-friendly, and newest fleet on the water hauling clean petroleum products. It provides seaborne transportation of crude oil and refined petroleum products. The company generates the majority of its revenue from LR2.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.